Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.51 |
| ▸ | GSK3B | P49841 | 5/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 3/20 | 0.40 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12954120 | 0.94 | CDK2 (0.49) | CDK2GSK3BEPHB4AURKARPS6KB1 | |
| SCHEMBL13289245 | 0.94 | CDK2 (0.49) | CDK2GSK3BEPHB4AURKARET | |
| SCHEMBL12954468 | 0.93 | CDK2 (0.51) | CDK2GSK3BEPHB4AURKARPS6KB1 | |
| SCHEMBL13289698 | 0.93 | CDK2 (0.56) | CDK2GSK3BEPHB4CNR1 | |
| SCHEMBL14301775 | 0.93 | CDK2 (0.49) | CDK2GSK3BAURKARETKDR | |
| SCHEMBL13289340 | 0.92 | CDK2 (0.48) | CDK2GSK3BRETKDR | |
| SCHEMBL13305356 | 0.92 | CDK2 (0.51) | CDK2GSK3B | |
| SCHEMBL13289326 | 0.91 | CDK2 (0.47) | CDK2GSK3BEPHB4AURKARPS6KB1 | |
| SCHEMBL13289534 | 0.91 | RET (0.48) | CDK2GSK3BRETKDR | |
| SCHEMBL13289563 | 0.91 | CDK2 (0.50) | CDK2GSK3BEPHB4AURKARPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080050384-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | CDK2 1/4885GSK3B 695/4885EPHB4 2963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.